Brief: GT Biopharma Appoints New Member To Its Board Of Directors
Brief: GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals
GT Biopharma Inc reports results for the quarter ended March 31 - Earnings Summary
GT Biopharma Inc expected to post a loss of 64 cents a share - Earnings Preview
Brief: GT Biopharma Appoints New Member To Its Board Of Directors
GT Biopharma Inc expected to post a loss of 64 cents a share - Earnings Preview
Brief: Gt Biopharma Receives Nasdaq Delisting Notice For Falling Below $2.5 Million Equity Minimum
Brief: Gt Biopharma Says Entered Into Investigator Initiated Clinical Trial Agreement With Regents Of University Of Minnesota
Brief: GT Biopharma Announces FDA Clearance Of Investigational New Drug Application For GTB-3650, An NK Cell Engager For Treatment Of CD33+ Leukemia
Brief: GT Biopharma Files For Resale Of Up To 740,000 Shares By Selling Shareholders
Brief: GT Biopharma Announces $3.2 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
GT Biopharma Inc expected to post a loss of $2.70 a share - Earnings Preview
GT Biopharma Inc reports results for the quarter ended in December - Earnings Summary
GT Biopharma Inc expected to post a loss of $2.70 a share - Earnings Preview
Brief: ISS And Glass Lewis, Recommend Gt Biopharma Stockholders Vote “For” All Proposed Items
Brief: GT Biopharma Announces Ind Submission For GTB-3650 For Treatment Of CD33+ Leukemia
GT Biopharma Inc reports results for the quarter ended in September - Earnings Summary
GT Biopharma Inc expected to post a loss of 10 cents a share - Earnings Preview
Brief: Gt Biopharma says That Co Has Until Feb 20, 2024, To Regain Nasdaq Minimum Bid Price Requirement Rule